Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients

NCT05202041 is registered in ClinicalTrials.gov with Wuhan Asia Heart Hospital as lead sponsor.

NCT NCT05202041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05202041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients
Lead sponsor
Wuhan Asia Heart Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
February 15, 2022
Completion date
March 30, 2023
Enrollment
500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, non st segment elevation acute coronary syndrome, percutaneous coronary intervention